Real-life efficacy and toxicity of lutetium peptide receptor radionuclide therapy in patients with progressive, metastatic neuroendocrine tumors who failed at least one line of systemic treatment

被引：0
|
作者：
Kavan, P. [1 ]
Rho, H. [1 ]
Probst, S. [2 ]
Abikhzer, G. [2 ]
Rho, Y. S. [3 ]
Barrera, I [1 ]
机构：
[1] McGill Univ, Segal Canc Ctr, Dept Med Oncol, Montreal, PQ, Canada
[2] Jewish Gen Hosp, Div Nucl Med, Montreal, PQ, Canada
[3] Univ Hawaii, John A Burns Sch Med, Honolulu, HI USA
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷
关键词：
neuroendocrine tumor; lutetium; prrt; efficacy; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H21
引用
收藏
页码：193 / 193
页数：1
相关论文
共 43 条
  • [1] Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumors
    Almeamar, H.
    Cullen, L.
    Murphy, D.
    Crowley, R.
    Skehan, S.
    Welin, S.
    O'Shea, D.
    O'Toole, D.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 136 - 136
  • [2] Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours
    Almeamar, Hussein
    Cullen, Lisa
    Murphy, David J.
    Crowley, Rachel K.
    Toumpanakis, Christos
    Welin, Staffan
    O'Shea, Donal
    O'Toole, Dermot
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 (06)
  • [3] Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children
    Foster, Jennifer H.
    Sher, Andrew
    Seghers, Victor
    Poston, Jay
    Wells, Donald
    Delpassand, Ebrahim S.
    Potter, Samara
    Mahajan, Priya
    Venkatramani, Rajkumar
    PEDIATRIC BLOOD & CANCER, 2021, 68 (07)
  • [4] Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors
    Alsadik, S. R.
    Gnanasegaran, G.
    Chen, L.
    Toumpanakis, C.
    Caplin, M.
    Navalkissoor, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 171 - 171
  • [5] Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors
    Gujarathi, Rushabh
    Tobias, Joseph
    Abou Azar, Sara
    Keutgen, Xavier M.
    Liao, Chih-Yi
    CANCERS, 2024, 16 (17)
  • [6] Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1,000 Patients from a Single Center
    Baum, R. P.
    Kulkarni, H.
    Zachert, C.
    Kaemmerer, D.
    Petrovitch, A.
    Niepsch, K.
    Hommann, M.
    Hoersch, D.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 282 - 282
  • [7] Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis
    Kim, Yong-il
    NUCLEAR MEDICINE COMMUNICATIONS, 2021, 42 (04) : 451 - 458
  • [8] Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors A Meta-analysis
    Saravana-Bawan, Bianka
    Bajwa, Amandeep
    Paterson, John
    McEwan, Alexander J. B.
    McMullen, Todd P. W.
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 719 - 727
  • [9] Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors
    Alayli, Adam
    Ngo, Hoang
    Sikaria, Dhiraj
    Ahmed, Altan
    Salloum, Elias
    Strosberg, Jonathan R.
    Al-Toubah, Taymeyah E.
    Kis, Bela
    Haider, Mintallah
    El-Haddad, Ghassan
    CANCERS, 2024, 16 (15)
  • [10] Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
    Jiang, Yuanyuan
    Liu, Qingxing
    Wang, Guochang
    Sui, Huimin
    Wang, Rongxi
    Wang, Jiarou
    Zhang, Jingjing
    Zhu, Zhaohui
    Chen, Xiaoyuan
    THERANOSTICS, 2022, 12 (15): : 6437 - 6445
12345